Tarius SAC Tracker®
Background Analysis: US FDA Joint Advisory Committee to Review Amgen’s T-Vec to Treat Metastatic Melanoma – APR 29, 2015 (CTGTAC-ODAC)
The SAC Tracker report for this meeting is only available for SAC Tracker Premium subscribers.
The SAC Tracker reports are available for FREE on this site until 10 days after the meeting is held.
To obtain unlimited access to SAC Tracker meeting reports back to 2010 and onwards, including the committee members' voting history, you must subscribe to the SAC Tracker Premium service.
METADATA: Sponsor: Amgen, Inc. Drug Name: talimogene laherparepvec Drug Class: oncolytic immunotherapy Indication: injectable regionally or distantly metastatic melanoma